SHANGHAI, China — Jemincare, a leading pharmaceutical company from China, announced that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., recently received 6 approvals of clinical trials for its innovative drugs in the field of cancer, kidney and anti-infectious diseases, including 4 approvals from National Medical Products Administration...
Latest News
SHANGHAI, China — In another milestone since the implementation of CAR-T therapy at Jiahui, the first myeloma patient treated with CAR-T at Jiahui International Hospital was recently discharged two weeks after infusion. The foreign patient was first diagnosed with multiple myeloma in 2008. Despite multiple treatments including chemotherapy, immunotherapy, target...
Changchun, China – Scientists have identified a new organelle in liver cells called the mitochondria-lysosome-related organelle (MLRO). This discovery could improve our understanding of chronic liver diseases like alcohol-associated liver disease (ALD) and metabolic dysfunction-associated fatty liver disease (MAFLD). Mitochondria are essential components of cells, often called the “powerhouses” because...
Changchun, China – While heavy drinking is a well-established risk factor for liver cancer, the specific mechanisms by which alcohol contributes to A-HCC remain unclear. This insightful review, published in Hepatology, provides a comprehensive summary of the pathogenesis, heterogeneity, preclinical approaches, epigenetic and genetic profiles of A-HCC. Compared to other types of...
Washington, D.C. – With ever-increasing life expectancy comes the challenge of treating age-related disorders such as osteoporosis. Although there are effective drugs for treating this metabolic bone disease, they can be expensive and have side effects, limiting their availability to some people. In the search for alternative drug candidates, researchers...
BOSTON, Mass. — Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with phenylketonuria (PKU). JNT-517, a small molecule inhibitor of the phenylalanine (Phe) transporter SLC6A19,...
LINZ, Austria – A new paper in Genome Biology and Evolution, published by Oxford University Press, finds that the link between paternal age and rare congenital disorders is more complex than scientists had previously thought. While researchers have long realized that older fathers are more likely to have children with...
Amsterdam, The Netherlands and San Antonio, TX, USA – John P. Cogswell, PhD, has been chosen as the recipient of the 2009 Alzheimer Award presented by the Journal of Alzheimer’s Disease in recognition of his outstanding work, “Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers...
Edison, New Jersey – Researchers at Hackensack Meridian’s John Theurer Cancer Center (JTCC), are part of a published Phase 3 study reporting on the equivalent safety and effectiveness in the oral treatment of blood cancers–such as myelodysplastic syndrome and/or chronic myelomonocytic leukemia–to its previously inpatient, intravenous treatment counterparts. John Theurer...
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center. The treatment included a histone deacetylase (HDAC) inhibitor — a drug that causes a chemical change to stop tumor cells from dividing...